Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Biomarkers In Multiple Sclerosis
Download Biomarkers In Multiple Sclerosis full books in PDF, epub, and Kindle. Read online Biomarkers In Multiple Sclerosis ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Biomarkers in Multiple Sclerosis by : U. Utz
Download or read book Biomarkers in Multiple Sclerosis written by U. Utz and published by IOS Press. This book was released on 2006-11 with total page 100 pages. Available in PDF, EPUB and Kindle. Book excerpt: Several processes are presumed to sequentially or simultaneously contribute to the pathophysiology of multiple sclerosis (MS). This work examines the potential of biomarkers in the context of MS. It explores the state of biomarker research for MS, barriers to progress and possible solutions and priorities.
Book Synopsis Biomarkers and Disease Activity in Multiple Sclerosis by : Irene Håkansson
Download or read book Biomarkers and Disease Activity in Multiple Sclerosis written by Irene Håkansson and published by Linköping University Electronic Press. This book was released on 2019-10-07 with total page 78 pages. Available in PDF, EPUB and Kindle. Book excerpt: This thesis focuses on disease activity in clinically isolated syndrome (CIS) and newly diagnosed relapsing remitting multiple sclerosis (RRMS). The papers are based on data from 41 patients in a prospective longitudinal cohort study. All patients were untreated at baseline. Age- and sex-matched healthy controls (n=22) for blood and cerebrospinal fluid (CSF) samples were recruited from blood donors. Paper I evaluated the prognostic value of baseline levels of CXCL1, CXCL8, CXCL10, CXCL13, CCL22, neurofilament light chain (NFL), neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9) and osteopontin in CSF in relation to disease activity during the first two years of follow-up. Disease activity was defined as clinical relapses, new T2 lesions in brain magnetic resonance imaging (MRI) and/or sustained Expanded Disability Status Scale (EDSS) progression. Absence of these three signs of disease activity was called no evidence of disease activity (NEDA-3). Logistic regression analysis showed that NFL in CSF was the best predictive marker of disease activity and correctly classified 93% of the patients with evidence of disease activity during two years of follow-up and 67% of those without. Paper II presented four year follow-up data from the cohort and also included brain volume data as well as serum levels of NFL. The correlation between NFL in CSF and serum was fairly strong (r=0.74, p<0.001). NFL in CSF was associated with new T2 lesions as well as with brain volume loss, whereas CHI3L1 in CSF was associated mainly with brain volume loss and CXCL1, CXCL10, CXCL13, CCL22 and MMP-9 in CSF were mainly associated with new T2 lesions. Taken together, paper I and II confirm and extend the knowledge of NFL as a useful biomarker in CIS and RRMS and suggests that NFL, rather than total brain volume loss, could be included in an expanded NEDA concept and used in clinical monitoring of disease activity/treatment effect. Although serum levels of NFL were correlated with the corresponding CSF levels, CSF-NFL showed a stronger association to subsequent disease activity (NEDA-3). Paper III addressed the patients´ self-reported Modified Fatigue Impact Scale (MFIS) scores in relation to other cohort study data. MFIS scores correlated with other self-assessment questionnaire data (Hospital Anxiety and Depression scale (HAD), Multiple Sclerosis Impact Scale 29 (MSIS-29) and Short Form 36 (SF-36) scores (Spearman´s rho 0.45-0.78, all p?0.01)) but not with EDSS ratings, number of T2 lesions, total brain volume or NFL levels, indicating that subjective fatigue scores are not well reflected by some commonly used and objectively measurable disease parameters. Paper IV focused on the complement factors C1q, C3, C3a and sC5b-9 in CSF and plasma. CSFC1q was significantly higher in patients than in controls at baseline. The subgroup of patients with ongoing relapse at baseline also had higher levels of CSF-C3a than controls. Baseline levels of CSF-C1q and CSF-C3a correlated significantly with several pro-inflammatory chemokines as well as with MMP-9, CHI3L1 and NFL in CSF. Baseline CSF-C3a also correlated significantly with the number of T2 lesions and Gadolinium enhancing lesions in brain MRI at baseline, as well as with the number of new T2 lesions during follow-up. This study indicates that the complement system is involved already at early stages of MS. It also suggests that especially CSF-C1q and CSF-C3a levels are associated with other neuroinflammatory and neurodegenerative markers and that CSF-C3a levels may carry some prognostic information.
Book Synopsis Biomarkers in Multiple Sclerosis by : Valentina Ignatova
Download or read book Biomarkers in Multiple Sclerosis written by Valentina Ignatova and published by . This book was released on 2018 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Clinical, biological, and radiological evidence are currently needed to diagnose MS, but lack of preclinical biomarkers hinders the earliest possible diagnosis and treatment. Conventional biomarkers target immunity, blood-brain barrier disruption, demyelination, and neuronal and axonal damage, as well as mitochondrial activity. An increase of specific brain metabolites with 30,Äì40% is registered before detection of MRI lesions in MS. Potential lipid biomarkers are fatty acids, phospholipids, and oxysterols. The role of proteoforms in the pathogenesis of MS was confirmed. Serum neurofilament light chains (sNfL) are currently being studied as a readily available biomarker for prognosis and response to treatment in MS. The sNfL levels reflect ongoing neuroaxonal damage caused by inflammation, and the sNfL levels predict disease activity over the next few years. The retinal nerve fiber layer (RNFL) thinning is reliable as a biomarker of disability worsening. The neutrophil-to-lymphocyte ratio and CRP are also MS biomarkers. The development of rationally targeted therapeutic agents that allow preventive treatment to stop the disease is also delayed without definite biomarkers.
Book Synopsis Neuroscience Biomarkers and Biosignatures by : Institute of Medicine
Download or read book Neuroscience Biomarkers and Biosignatures written by Institute of Medicine and published by National Academies Press. This book was released on 2008-02-08 with total page 128 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.
Book Synopsis Reassessing the immune system contribution in multiple sclerosis: Therapeutic target, biomarkers of disease and immune pathogenesis by : Maria Teresa Cencioni
Download or read book Reassessing the immune system contribution in multiple sclerosis: Therapeutic target, biomarkers of disease and immune pathogenesis written by Maria Teresa Cencioni and published by Frontiers Media SA. This book was released on 2023-04-10 with total page 220 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Multiple Sclerosis and Related Disorders: Challenges and Approaches to Mechanisms, Biomarkers, and Therapeutic Targets by : Jinzhou Feng
Download or read book Multiple Sclerosis and Related Disorders: Challenges and Approaches to Mechanisms, Biomarkers, and Therapeutic Targets written by Jinzhou Feng and published by Frontiers Media SA. This book was released on 2024-05-28 with total page 119 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple sclerosis (MS) is an autoimmune condition that causes inflammatory damage to the central nervous system. The pathologic features are diffuse and focal inflammation, demyelination, gliosis, and neuronal damage in the optic nerves, brain, and spinal cord. Multiple sclerosis remains a challenging and disabling disease. There is a greater understanding of the underlying genetic and environmental factors driving the disorder, including low vitamin D levels, smoking, and obesity. Early and accurate diagnosis is essential and needs to be supported by diagnostic criteria, including imaging and spinal fluid abnormalities in patients with clinically isolated syndromes. Other demyelinating diseases are neuromyelitis optica spectrum disorders (NMOSD), anti-myelin oligodendrocyte glycoprotein antibody disease (MOGAD), and acute disseminated encephalomyelitis (ADEM).
Book Synopsis Biomarkers of Brain Injury and Neurological Disorders by : Kevin K. W. Wang
Download or read book Biomarkers of Brain Injury and Neurological Disorders written by Kevin K. W. Wang and published by CRC Press. This book was released on 2014-10-28 with total page 647 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explores the recent advances in the techniques and platforms used in biomarker research that have revolutionized the way we study, diagnose, and treat brain injury conditions. The contributors describe different biomarker studies pertaining to brain injury and other neurological disorders and analyze the different models and technologies
Author :National Academies of Sciences, Engineering, and Medicine Publisher :National Academies Press ISBN 13 :0309463688 Total Pages :89 pages Book Rating :4.3/5 (94 download)
Book Synopsis Biomarkers of Neuroinflammation by : National Academies of Sciences, Engineering, and Medicine
Download or read book Biomarkers of Neuroinflammation written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-02-16 with total page 89 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neuroinflammation is a burgeoning area of interest in academia and biopharma, with a broadly acknowledged role in many central nervous system (CNS) disorders. However, there is little agreement on the pathophysiological mechanisms that underlie the manifestations of neuroinflammation in the CNS compartment and how neuroinflammation operates as a driver and also as a consequence of disease in the brain. Moreover, another unclear area is how to translate increased understanding of the mechanisms that underlie neuroinflammation and its manifestations in the CNS to therapeutics. To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20-21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of CNS diseases. The workshop also considered strategies to advance the identification and validation of biomarkers of neuroinflammation that could accelerate development of therapies, bringing much-needed treatments to patients with disorders ranging from neuroinflammatory diseases such as multiple sclerosis (MS) to neuropsychiatric disorders such as depression. This publication summarizes the presentations and discussions from the workshop.
Book Synopsis Multiple Sclerosis by : Howard L. Weiner
Download or read book Multiple Sclerosis written by Howard L. Weiner and published by John Wiley & Sons. This book was released on 2012-02-15 with total page 331 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple Sclerosis: a complex disease requiring sophisticated management Multiple Sclerosis poses labyrinthine challenges. There is no blood test to rely on for diagnosis; clinical acumen is essential. Yet an effective diagnosis only takes you part of the way: treatment offers further enigmas. The MS treatment landscape is complicated, and will become even more so with time. Multiple Sclerosis: Diagnosis and Therapy is the map you need to navigate this maze. Written and edited by leaders in the field, it guides you towards effective and positive choices for your patients. The diagnosis section provides state-of-the-art thinking about pathogenesis. With clear coverage of biomarkers, genetics, and imaging, it presents a coherent framework for making the correct diagnosis. The management section comprehensively covers current and future treatments to steer you through the many options for • Symptom management • Cognitive dysfunction • Depression and other mental health issues ‘Top Tips’ throughout provide the practical guidance you need for the best management of your patients. Multiple Sclerosis: Diagnosis and Therapy should be on the bookshelf of anyone who treats patients with multiple sclerosis.
Book Synopsis Multiple Sclerosis by : Michael Olek
Download or read book Multiple Sclerosis written by Michael Olek and published by Springer Science & Business Media. This book was released on 2007-10-27 with total page 253 pages. Available in PDF, EPUB and Kindle. Book excerpt: A synthesis of current concepts about the evaluation, treatment, and future directions in MS. On the evaluation side, the authors review the use of MRI, magnetic resonance spectroscopy, functional MRI, and three-dimensional MRI, and consider the rapidly developing body of pathologic information they have yielded. On the treatment side, the focus is on recently approved medications (Novantrone), new indications for medications (CHAMPS Trial), medications in development (Oral Interferon Tau, Oral Copaxone, and Oral Cellcept), immunosuppressive therapy for both progressive disease and symptomatic therapy; the current medications for treating relapsing-remitting MS (Avonex, Betaseron, and Copaxone) are also discussed. For future directions, the authors present the current best thinking, as well as the latest discoveries in immunology relating to MS, including groundbreaking B-cell research and its applications to specific immunotherapies, and the use of immune markers for tracking the disease.
Book Synopsis Multiple Sclerosis 3, Volume 34 E-Book by : Claudia Lucchinetti
Download or read book Multiple Sclerosis 3, Volume 34 E-Book written by Claudia Lucchinetti and published by Elsevier Health Sciences. This book was released on 2009-10-29 with total page 487 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple Sclerosis 3 emphasizes the latest in the pharmacologic treatment of this incurable inflammatory demyelinating disorder. Primary editors Claudia Lucchinetti, MD, and Reinhard Hohlfeld, MD, with the aid of all new contributors, present a complete and current reference on multiple sclerosis that includes discussions of such hot topics as Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair. Distinguish between MS and other similar demyelinating disorders and know the best and most aggressive methods of treatment. This title in the Blue Books of Neurology series is exactly what you need to treat the disease and its relapses. Covers the latest clinical advances and relevant discussions—Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair—to bring you up to date and keep your practice state-of-the-art. Features a greater emphasis on practical management to help you determine the type of multiple sclerosis and the best course of therapy. Focuses on pharmaceutical therapies so you know the best and most aggressive methods and which drugs to use for treatment. Includes extensive information on differential diagnosis so that you can clearly distinguish between multiple sclerosis and other similar demyelinating disorders. Presents expert new editors and experienced contributing authors for the most current and relevant practice information. Emphasizes the pharmacologic management of patients with multiple sclerosis to address treating the actual disease and its relapses as well as treating the symptoms.
Book Synopsis Developing New Imaging Biomarkers in Multiple Sclerosis by : Niamh Cawley
Download or read book Developing New Imaging Biomarkers in Multiple Sclerosis written by Niamh Cawley and published by . This book was released on 2016 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Biomarkers of Neurological and Psychiatric Disease by :
Download or read book Biomarkers of Neurological and Psychiatric Disease written by and published by Academic Press. This book was released on 2011-10-29 with total page 471 pages. Available in PDF, EPUB and Kindle. Book excerpt: Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia. Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist
Book Synopsis Pathophysiologic Insights from Biomarker Studies in Neurological Disorders by : Tobias Ruck
Download or read book Pathophysiologic Insights from Biomarker Studies in Neurological Disorders written by Tobias Ruck and published by Frontiers Media SA. This book was released on 2020-04-01 with total page 340 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Multiple Sclerosis by : Uday Kishore
Download or read book Multiple Sclerosis written by Uday Kishore and published by BoD – Books on Demand. This book was released on 2024-01-31 with total page 134 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple sclerosis (MS) is a lifelong neurological condition that has no known cure. This book provides an extensive exploration of current and future directions for understanding immunology, neuroscience, and the development of potent treatment modalities. It presents an in-depth analysis and expert commentary on the role of genetics, lifestyle factors, biomarkers, neuroimaging, cognitive domains, artificial intelligence, and innate immunity in MS pathogenesis. We hope that the book is helpful to readers of all spheres of life, including those who want to understand more about MS, those who are keen to improve their understanding of MS disease pathogenesis, those who are enthusiastic to know more about treatment modalities, and those who want to be informed about state-of-the-art clinical developments in MS.
Book Synopsis Developing New Imaging Biomarkers in Multiple Sclerosis by : N. M. Cawley
Download or read book Developing New Imaging Biomarkers in Multiple Sclerosis written by N. M. Cawley and published by . This book was released on 2016 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Biomarkers in Autoimmune Diseases of the Central Nervous System by : Mei-Ping Ding
Download or read book Biomarkers in Autoimmune Diseases of the Central Nervous System written by Mei-Ping Ding and published by Frontiers Media SA. This book was released on 2023-09-25 with total page 219 pages. Available in PDF, EPUB and Kindle. Book excerpt: Autoimmune diseases of the central nervous system (CNS) are a group of complex and disabling disorders characterized by the immune system mistakenly attacking the CNS. During the last 2 decades, we have witnessed a rapidly evolving spectrum of CNS autoimmune diseases, which has become a research hotspot in neurology. These include CNS inflammatory demyelinating diseases such as multiple sclerosis and neuromyelitis optical spectrum disorders, paraneoplastic, and other autoimmune encephalomyelitis and CNS involvement in systemic autoimmune diseases. Recently, although remarkable discoveries have accumulated more understanding of the autoimmune basis behind the physiopathologic mechanism, the exact pathogenic processes are still unclear. Patients may present with a variety of manifestations, posing a great challenge to diagnosis and management. The determination of biomarkers plays a significant role in CNS autoimmune diseases. Biomarkers can reflect the presence, nature, and intensity of certain immune responses triggered by both genetic and environmental processes, and bear great importance in guiding clinical diagnosis, estimating disease risk or prognosis, evaluating disease severity, and monitoring progression or response to therapy. For instance, the detection of disease-specific antibodies can contribute to the accurate diagnosis and precise treatment. Moreover, identifying the diverse biomarkers could further help to achieve the ultimate goal of personalized medicine.
